1996
DOI: 10.1016/0750-7658(96)82151-4
|View full text |Cite
|
Sign up to set email alerts
|

Urapidil au cours de la chirurgie du phéochromocytome: commencer dès la phase préopératoire

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2002
2002
2009
2009

Publication Types

Select...
4

Relationship

3
1

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 3 publications
0
2
0
Order By: Relevance
“…Pre-and per-operative urapidil by intravenous perfusion with dosage matched to blood pressure, as has been described for the laparoscopic removal of unilateral pheochromocytomas, 15,16 was used with success in our bilateral intervention. In our patient (Table 1), the sharp increase in plasma cathecholamine levels after pneumoperitoneum and manipulation of each tumor underlines the need for adequate alpha receptor blockade and the clear-cut fall in catecholamine levels following removal of each tumor confirmed the bilateral nature of the disorder.…”
Section: Comments On the Surgical Approach By Laparoscopymentioning
confidence: 99%
“…Pre-and per-operative urapidil by intravenous perfusion with dosage matched to blood pressure, as has been described for the laparoscopic removal of unilateral pheochromocytomas, 15,16 was used with success in our bilateral intervention. In our patient (Table 1), the sharp increase in plasma cathecholamine levels after pneumoperitoneum and manipulation of each tumor underlines the need for adequate alpha receptor blockade and the clear-cut fall in catecholamine levels following removal of each tumor confirmed the bilateral nature of the disorder.…”
Section: Comments On the Surgical Approach By Laparoscopymentioning
confidence: 99%
“…7±9 It is of pivotal importance to limit the effects of such release through preoperative preparation of the patient and perioperative use of drugs that block the effects of catecholamines on a 1 receptors. 10 However, there is a risk of severe hypotension after the tumour removal when long acting a 1 blockers are used. Urapidil, a competitive and selective short acting a 1 blocker is also an agonist at central serotoninergic receptors.…”
mentioning
confidence: 99%